These findings are in accord with the results of the previous studies that up-regulated ANXA2 correlated with the clinical aggressiveness in renal cancer, endometrial cancer and colorectal carcinoma [20–22]. This evidence concerns the gene ANXA2 and colorectal carcinoma.